When sporotrichosis is diagnosed during pregnancy, the standard antifungal options must be reconsidered. The safety profile constraints of pregnancy significantly narrow the therapeutic choice, and the optimal approach depends on how severe and extensive the infection is.
Active sporotrichosis in a pregnant patient. Pregnancy is the defining comorbidity here — it directly limits which antifungal agents can be used and shapes the entire management approach.
For severe sporotrichosis that must be treated during pregnancy, an amphotericin B-based regimen is the indicated pathway; a widely used class of oral antifungals is contraindicated in this setting. For cutaneous disease in pregnant patients, a local non-pharmacological intervention is an option. The complete evidence-based algorithm — including agent selection, clinical decision points, and the criteria that determine which pathway applies — is in the full protocol.
DOI: 10.1086/522765